NDAORALTABLET
Approved
Nov 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALPIN 50 (anisotropine methylbromide) is an oral anticholinergic agent approved in 1962 for gastrointestinal indications. It functions as a muscarinic receptor antagonist to reduce gastric acid secretion and smooth muscle spasm. This legacy small-molecule product represents a mature therapeutic class with limited modern clinical application.
LOE Approaching
Legacy product with declining franchise value; commercial team likely focused on defensive positioning and market maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VALPIN 50 represents a career assignment in legacy product stewardship with zero linked job openings, indicating minimal hiring and limited advancement potential. Professionals assigned to this brand typically focus on defending market share and managing regulatory compliance rather than driving innovation or revenue growth.
Brand Manager (legacy portfolio)Medical Science Liaison (defensive)
Worked on VALPIN 50 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.